Anzeige
Mehr »
Login
Freitag, 10.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Innocan Pharma News: Unfassbare Studie - LPT-Therapie bewahrt Patient vor dem Tod!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
463 Leser
Artikel bewerten:
(1)

CryoLife, Inc. Announces Corporate Rebranding and Changes Name to Artivion

ATLANTA, Jan. 18, 2022 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it was renaming and rebranding itself to Artivion, Inc., effective immediately. Derived from the words "aorta", "innovation", and "vision", the company's new name and brand reflect its evolution to focus on providing innovative technologies to surgeons who treat patients with aortic disease. In conjunction with these changes, effective January 24, 2022, the company will also change its ticker symbol on the New York Stock Exchange to "AORT" from "CRY."

"Through a combination of legacy products and strategic acquisitions and divestitures over the last five years, we have transformed from a tissue and adhesives focused company to one with a premier portfolio of aortic products," said Pat Mackin, Chairman, President and Chief Executive Officer of Artivion. "Today marks an important milestone for our company. We look forward to embarking on our next chapter as a leader in developing simple, elegant solutions to address cardiac and vascular surgeons' most difficult clinical challenges in treating patients with aortic disease."

Artivion will discuss its business, its strategy, and the rebrand at an Investor & Analyst Day on March 23, 2022, in New York City. Details of the event will be provided at a later date.

About Artivion, Inc.
Headquartered in suburban Atlanta, Georgia, Artivion, Inc. (Artivion) is a medical device company focused on developing simple, elegant solutions that address cardiac and vascular surgeons' most difficult clinical challenges in treating patients with aortic diseases. This multinational company's four major groups of products include: aortic stents and stent grafts, prosthetic heart valves, cryopreserved cardiac and vascular allografts, and surgical sealants. Artivion markets and sells products in more than 100 countries worldwide. For additional information about Artivion, visit our website, www.artivion.com, accessible by the end of day today.

Contacts:

CryoLife       
D. Ashley Lee                                                
Executive Vice President, Chief Financial Officer
and Chief Operating Officer
Phone: 770-419-3355

Gilmartin Group LLC
Brian Johnston / Lynn Lewis
Phone: 631-807-1986

  

SOURCE CryoLife, Inc.; Artivion, Inc.

Lithium vs. Palladium - Ist das die Chance des Jahrzehnts?
Sichern Sie sich den kostenlosen PDF-Report! So können Sie vom Boom der Rohstoffe profitieren.
Hier klicken
© 2022 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.